Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques.


Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
10 May 2024
Historique:
received: 24 01 2024
revised: 21 04 2024
accepted: 09 05 2024
medline: 12 5 2024
pubmed: 12 5 2024
entrez: 12 5 2024
Statut: aheadofprint

Résumé

HTLV-1 infection occurs by cell-to-cell transmission and can induce fatal adult T-cell leukemia (ATL). Vaccine development is critical for the control of HTLV-1 transmission. However, determining whether vaccine-induced anti-Env antibodies can prevent cell-to-cell HTLV-1 transmission is challenging. Here, we examined the protective efficacy of a vaccine inducing anti-Env antibodies against HTLV-1 challenge in cynomolgus macaques. Eight of ten vaccinated macaques produced anti-HTLV-1 neutralizing antibodies (NAbs) and were protected from an intravenous challenge with 10

Identifiants

pubmed: 38734900
pii: S1525-0016(24)00323-X
doi: 10.1016/j.ymthe.2024.05.020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Midori Nakamura-Hoshi (M)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Hiroshi Ishii (H)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Takushi Nomura (T)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.

Masako Nishizawa (M)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Trang Thi Thu Hau (TT)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Nozomi Kuse (N)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Midori Okazaki (M)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Akira Ainai (A)

Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Tadaki Suzuki (T)

Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.

Hideki Hasegawa (H)

Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Takeshi Yoshida (T)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Kenzo Yonemitsu (K)

Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Yuriko Suzaki (Y)

Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Yasushi Ami (Y)

Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.

Hiroyuki Yamamoto (H)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan; Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.

Tetsuro Matano (T)

AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan; Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. Electronic address: tmatano@niid.go.jp.

Classifications MeSH